BridgeMD
The MIRAGE study. Use of radioactively labelled deferoxamine for a novel purpose: imaging pulmonary aspergillosis with PET/CT scans.
EU CTIS ID: 2023-509744-10-00
What this study is testing
To demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT for the visualization of pulmonary Aspergillus infection.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The patient is at least 18 years old on the day of inclusion.
- The patient has suspected chronic pulmonary aspergillosis or ABPA.
- There is no significant interference with standard care and follow-up.
You likely can't join if
- The patient is pregnant or planning on becoming pregnant.
- The patient has severe kidney dysfunction with eGFR < 30 ml/min/kg and/or receives dialysis.
- The patient has (chronic) iron overload.
- The patient has been receiving antifungal treatment for more than 48 hours prior to the study day.
- The patient is not able to lie still in the scanner.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.